Other Events · Jun 8, 2026

Sanofi announced that the US FDA has accepted venglustat for priority review for the treatment of type 3 Gaucher disease

SNYSanofi

Sanofi announced that the US FDA has accepted venglustat for priority review for the treatment of type 3 Gaucher disease.

More from Sanofi

Sanofi breaks ground on new insulin manufacturing facility in FrankfurtOct 26, 2026
Sanofi pays Regeneron $1B upfront plus up to $7B in milestones for expanded immunology allianceOct 1, 2026
Sanofi announced a strategic partnership with Cheplapharm to divest a selection of 20 mature medicines and three…Sep 17, 2026
Sanofi announced the discontinuation of clinical development for amlitelimab, an OX40-ligand monoclonal antibody, in…Jul 27, 2026
The US Food and Drug Administration (FDA) approved subcutaneous Sarclisa Escena for the treatment of patients with…Jul 17, 2026

Explore SNY